Quarterly ResultMay 11, 2026, 04:13 PM
Kyntra Bio Q1 Revenue $3.7M; Net Loss Improves to $15.1M
AI Summary
Kyntra Bio reported first-quarter 2026 financial results, with total revenue increasing to $3.7 million from $2.7 million year-over-year. The net loss from continuing operations improved to $15.1 million, or $3.74 per share, compared to a $16.8 million loss in the prior year. The company also provided positive business updates, including progress in its Phase 2 trial for FG-3246 in mCRPC, with interim analysis expected in Q4 2026, and finalization of the Phase 3 trial protocol for roxadustat following FDA feedback, targeting a H2 2026 initiation. Kyntra Bio maintains a strong cash position of $100.3 million, providing a cash runway into 2028.
Key Highlights
- Total revenue for Q1 2026 increased to $3.7 million from $2.7 million in Q1 2025.
- Net loss from continuing operations improved to $15.1 million ($3.74/share) from $16.8 million ($4.15/share) YoY.
- Cash, cash equivalents, investments, and accounts receivable totaled $100.3 million as of March 31, 2026.
- Cash runway is projected to extend into 2028.
- Phase 2 monotherapy trial of FG-3246 in mCRPC is on track for interim analysis in Q4 2026.
- Positive results from FG-3246 combination study in mCRPC showed median rPFS of 7.0 months.
- Pivotal Phase 3 trial protocol for roxadustat in LR-MDS is being finalized after FDA feedback.
- Phase 3 trial for roxadustat is anticipated to initiate in the second half of 2026.
Price Impact
More from KYNB